These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8376683)

  • 21. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
    Wilson RM; De Silva DS; Sato K; Izumiya Y; Sam F
    Hypertension; 2009 Sep; 54(3):583-90. PubMed ID: 19620510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.
    Steimle AE; Stevenson LW; Chelimsky-Fallick C; Fonarow GC; Hamilton MA; Moriguchi JD; Kartashov A; Tillisch JH
    Circulation; 1997 Aug; 96(4):1165-72. PubMed ID: 9286945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
    Chatterjee K; Massie B; Rubin S; Gelberg H; Brundage BH; Ports TA
    Am J Med; 1978 Jul; 65(1):134-45. PubMed ID: 99031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of venodilation during long-term vasodilator therapy of chronic left ventricular failure.
    Franciosa JA; Leddy CL; Schwartz DE
    Z Kardiol; 1983; 72 Suppl 3():168-72. PubMed ID: 6666217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspects on "traditional" vasodilators in the treatment of chronic heart failure.
    Rydén L; Conradson TB
    Acta Med Scand Suppl; 1986; 707():85-90. PubMed ID: 3526822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
    Walsh WF; Greenberg BH
    Circulation; 1981 Sep; 64(3):499-505. PubMed ID: 7261282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical therapy and prognosis in chronic heart failure. Lessons from clinical trials.
    Ramahi TM; Lee FA
    Cardiol Clin; 1995 Feb; 13(1):5-26. PubMed ID: 7796432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
    Mahgoub AA; El-Medany AH; Abdulatif AS
    Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.
    Remme WJ
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):375-96. PubMed ID: 2487535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of peripheral vasodilators with different mechanisms of action in treating heart failure patients].
    Novikov SV; Mareev VIu; Elizarova NA; Naumov VG; Sazonova LN
    Ter Arkh; 1987; 59(9):126-30. PubMed ID: 3424177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy].
    Moriuchi M; Saito S; Tamura Y; Kaseda N; Tsuji M; Tokutake E; Yumikura S; Hibiya K; Ozawa Y; Hatano M
    J Cardiogr Suppl; 1986; (9):77-85. PubMed ID: 3093596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolving role of angiotensin-converting enzyme inhibition in heart failure: expanding the protective envelope.
    Teerlink JR
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S32-7. PubMed ID: 7700062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin, and their combination.
    Ribner HS; Zucker MJ; Stasior C; Talentowski D; Stadnicki R; Lesch M
    Am Heart J; 1987 Jul; 114(1 Pt 1):91-6. PubMed ID: 3604877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure.
    Cohn JN
    Am J Cardiol; 1993 Sep; 72(8):21C-24C; discussion 24C-26C. PubMed ID: 8372797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure.
    Colucci WS; Williams GH; Alexander RW; Braunwald E
    Am J Med; 1981 Jul; 71(1):89-99. PubMed ID: 6166194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of vasodilator therapy on mortality in chronic congestive heart failure.
    Ghose JC; Chakraborty S; Mondal M; Bhandari B
    J Assoc Physicians India; 1993 May; 41(5):269-71. PubMed ID: 8300456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasodilators in heart failure secondary to coronary artery disease.
    Parmley WW; Rouleau JL; Chatterjee K
    Am Heart J; 1982 Apr; 103(4 Pt 2):625-32. PubMed ID: 7064804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.